Brief: Shuttle Pharma's Selective Hdac6 Inhibitor Shown To Stimulate Innate Immune Response In Pre-Clinical Studies

Shuttle Pharmaceuticals Holdings

29/08/2023 14:12

Aug 29 (Reuters) - Shuttle Pharmaceuticals Holdings Inc
 SHPH.O :
    * SHUTTLE PHARMA'S SELECTIVE HDAC6 INHIBITOR SHOWN TO
STIMULATE
INNATE IMMUNE RESPONSE IN PRE-CLINICAL STUDIES, AS REPORTED IN
MOLECULAR CANCER THERAPEUTICS

Source text for Eikon:  ID:nPn636HHda 
Further company coverage:  SHPH.O